SURMOUNT BIO Trademark

Trademark Overview


On Thursday, July 18, 2019, a trademark application was filed for SURMOUNT BIO with the United States Patent and Trademark Office. The USPTO has given the SURMOUNT BIO trademark a serial number of 88521089. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 16, 2023. This trademark is owned by ElevateBio, LLC. The SURMOUNT BIO trademark is filed in the Pharmaceutical Products category with the following description:

Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical...
surmount bio

General Information


Serial Number88521089
Word MarkSURMOUNT BIO
Filing DateThursday, July 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 16, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 15, 2019

Trademark Statements


Goods and ServicesGene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Biological preparations for the treatment of cancer; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a capsule, pill, or liquid that facilitate the delivery of pharmaceutical preparations; Medical preparations for the treatment of cancer, cystic fibrosis, heart disease, and AIDS; Medicinal infusions for treating Cancer, cystic fibrosis, heart disease, and AIDS; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations for the treatment and prevention of Cancer, cystic fibrosis, heart disease, and AIDS; Pharmaceutical products for the prevention and treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Therapeutic pharmaceutical for the treatment of Cancer, cystic fibrosis, heart disease, and AIDS; Unit dose capsules sold empty for pharmaceutical use
Disclaimer with Predetermined Text"BIO"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 25, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameElevateBio, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Party NameElevateBio, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Tuesday, January 17, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 16, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, May 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 19, 2022SOU EXTENSION 5 GRANTED
Tuesday, May 17, 2022SOU EXTENSION 5 FILED
Tuesday, May 17, 2022SOU TEAS EXTENSION RECEIVED
Friday, November 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 24, 2021SOU EXTENSION 4 GRANTED
Wednesday, November 24, 2021SOU EXTENSION 4 FILED
Wednesday, November 24, 2021SOU TEAS EXTENSION RECEIVED
Thursday, November 18, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 18, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, November 18, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, November 18, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, June 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 10, 2021SOU EXTENSION 3 GRANTED
Thursday, June 10, 2021SOU EXTENSION 3 FILED
Thursday, June 10, 2021SOU TEAS EXTENSION RECEIVED
Thursday, June 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, June 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, January 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 22, 2021SOU EXTENSION 2 GRANTED
Thursday, December 10, 2020SOU EXTENSION 2 FILED
Tuesday, January 12, 2021NOTICE OF REVIVAL - E-MAILED
Monday, January 11, 2021SOU EXTENSION RECEIVED WITH TEAS PETITION
Monday, January 11, 2021PETITION TO REVIVE-GRANTED
Monday, January 11, 2021TEAS PETITION TO REVIVE RECEIVED
Monday, January 11, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 11, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, September 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 9, 2020SOU EXTENSION 1 GRANTED
Wednesday, June 10, 2020SOU EXTENSION 1 FILED
Wednesday, September 2, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 14, 2020NOTICE OF REVIVAL - E-MAILED
Tuesday, July 14, 2020SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, July 14, 2020PETITION TO REVIVE-GRANTED
Tuesday, July 14, 2020TEAS PETITION TO REVIVE RECEIVED
Monday, July 13, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 13, 2020ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 10, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 15, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 15, 2019PUBLISHED FOR OPPOSITION
Wednesday, September 25, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 9, 2019ASSIGNED TO LIE
Thursday, September 5, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 3, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 2, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 2, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, August 31, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, August 31, 2019NON-FINAL ACTION E-MAILED
Saturday, August 31, 2019NON-FINAL ACTION WRITTEN
Thursday, August 29, 2019ASSIGNED TO EXAMINER
Thursday, July 25, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 22, 2019NEW APPLICATION ENTERED